Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Gary Middleton(University of Birmingham), John P. Neoptolemos(University of Liverpool), Stephen Falk(At Bristol), Jonathan Wadsley(Weston Park Cancer Centre), Richard Jackson(University of Liverpool), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Charlotte Rawcliffe(University of Liverpool), Paula Ghaneh(University of Liverpool), Daniel H. Palmer(Cancer Research UK Clinical Trials Unit), Tamas Hickish(Southampton General Hospital), William Greenhalf(University of Liverpool), Nick Wadd(South Tees Hospitals NHS Foundation Trust), David Propper(St Bartholomew's Hospital), A.G. Evans(Harvard University), David Cunningham(Royal Marsden NHS Foundation Trust), Victoria Shaw(University of Liverpool), Pippa Corrie(Cambridge University Hospitals NHS Foundation Trust), Harpreet Wasan(Peter MacCallum Cancer Centre), Juan W. Valle(The Christie NHS Foundation Trust), Trevor F. Cox(University of Liverpool), Paul J. Ross(Guy's and St Thomas' NHS Foundation Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Fiona Campbell(University of Liverpool), Eithne Costello(University of Liverpool)
Cited by 73
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Spontaneous formation of ordered structures in thin films of metals supported on an elastomeric polymer
|Nature|1998|2.3k
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k